Table 1 Current and future trials of menin inhibitors in pediatric patients.
Current | |||||
|---|---|---|---|---|---|
Clinical trial/sponsor | Phase | Treatment | Biomarkers | Age eligibility | Location |
AUGMENT-101 (NCT04065399) | 1/2 | Revumenib monotherapy | KMT2A-r, NPM1-m, NUP98-r | All ages; AML and ALL | Multisite- U.S. and Europe |
AUGMENT-102 (NCT05326516) | 1 | Revumenib + FLA | KMT2A-r, NPM1-m, NUP98-r | All ages AML and ALL | Multisite- U.S. and Europe |
SAVE (NCT05360160) | 1/2 | Revumenib + Venetoclax+ ASTX727 | KMT2A-r, NPM1-m, NUP98-r (Frontline and Relapse) | ≥12 years AML and MPAL | MD Anderson Cancer Center |
TINI 2 (NCT05848687) | 1 | Ziftomenib + Multiagent | KMT2A-r | Infant ALL | Stanford University |
AALL2121 / COG (NCT05761171) | 2 | Revumenib + Multiagent | KMT2A-r | 30 days to 6 years ALL and MPAL | Multisite US |
(NCT04811560) | 1 | JNJ-75276617 + Multiagent | KMT2A-r, NPM1-m, NUP98-r, NUP214-r | >12 years. AML and ALL | Multisite- US and Europe |
(NCT06177067) | 1 | Revumenib + Venetoclax + Azacytidine. | KMT2A-r, NPM1-m, NUP98-r | 1-30yo. AML and ALL | St Jude Children’s Hospital |
FUTURE | |||||
| Â | 1 | Ziftomenib + Venetoclax + Azacytidine | KMT2A-r, NPM1-m, NUP98-r | <40 yo; AML and ALL | MD Anderson Cancer Center |
APAL2020K ITCC-101/COG/PEDAL | 1 | Ziftomenib + FLA | KMT2A-r, NPM1-m, NUP98-r | <18 yo; AML and ALL | Multisite- U.S. and Europe |
| Â | 1 | Ziftomenib + Venetoclax + Gemtuzumab | KMT2A-r, NPM1-m, NUP98-r, UBTF-ITD | <40 yo; AML and ALL | MD Anderson Cancer Center |
| Â | 1 | Revumenib + AD + Gemtuzumab | KMT2A-r, NPM1-m, NUP98-r, UBTF-ITD | <40 yo; AML and ALL | MD Anderson Cancer Center |
